Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease

Campbell, Ashley A.

doi:10.1001/jamaophthalmol.2021.6376

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Teprotumumab is a fully human monoclonal antibody targeting the IGF-IR. It was found to be useful in improving the proptosis, diplopia, and quality of life of TED patients [50,52 ▪▪ ,53,61,62,63 ▪▪ ]. Tocilizumab, which blocks interleukin 6 (IL-6), also demonstrated efficacy in improving the extraocular motility in 83.33%, and diplopia in 53.85% of TED patients [53,54].…”

Section: Thyroid Eye Diseasementioning

confidence: 99%

Nonneurologic causes of binocular diplopia for the neurologist

Mosleh¹,

Peragallo

2022

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewTo review several etiologies of nonneurologic diplopia that the neurologist should be familiar with. The pathophysiology, clinical presentation, neuroimaging findings, and treatment options are briefly summarized for each condition. Recent findingsCertain etiologies for diplopia can be associated with life-threatening neurologic conditions and should be investigated thoroughly for proper localization and immediate management of the underlying disease. However, nonneurological causes of binocular diplopia are very common and disabling, but are often nonemergent and may not require in-depth investigation or neuroimaging. Some of the etiologies of nonneurologic diplopia mimic cranial nerve palsies, making them confusing to evaluate when the physician is not familiar with these etiologies. Unfamiliarity with these diagnoses can lead to unnecessary neuroimaging, inefficient utilization of medical resources, and undue alarm to the patient. Recent advances in clinical diagnostic tools and neuroimaging have clarified our understanding of the diverse underlying mechanisms of nonneurologic binocular diplopia. SummaryDiplopia can be a difficult symptom for the neurologist to evaluate. A systematic approach to the evaluation of diplopia can help establish the urgency and necessity of an extensive workup. This review will help to familiarize the neurologist with nonneurological causes of binocular diplopia, minimize expensive and unnecessary evaluations, and reassure patients and physicians alike.

show abstract

Section: Thyroid Eye Diseasementioning

confidence: 99%

Nonneurologic causes of binocular diplopia for the neurologist

Mosleh¹,

Peragallo

2022

Current Opinion in Neurology

View full text Add to dashboard Cite

show abstract

Surgical management of dysthyroid optic neuropathy: A systematic review

Meunier,

Haissaguerre,

Majoufre

et al. 2024

Journal of Stomatology, Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review

Mehmood,

Rizvi,

Alam

et al. 2024

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, is an autoimmune disorder caused due to a complex interplay between autoantigens including the thyroid-stimulating hormone receptor and the insulin-like growth factor-I receptor. TED is characterized by progressive proptosis or diplopia. This systematic review aimed to compare the efficacy of the newer monoclonal antibody – teprotumumab and intravenous methylprednisolone (IVMP) in TED patients. We performed a systematic review of previously published studies from 2013 to June 2023. A total of 329 articles were screened; among them, 111 non-duplicate publications were identified. After the screening of titles and abstracts, 156 publications were excluded; then, another 47 published papers were excluded after the full-text screening. The remaining 15 eligible studies were included in this systematic review. The majority of studies used either teprotumumab alone or in combination with others. Among 15 studies, eight studies used teprotumumab in TED patients, whereas remaining 7 studies used a standard treatment regimen. This systematic review provides an overview of the existing treatment options using monoclonal antibody – teprotumumab and IVMP in TED patients. The overall assessment provides a finding that antibody – teprotumumab is is a good choice compared to conventional IVMP for providing better outcomes in patients with TED.

show abstract

Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease

Cited by 3 publications

References 8 publications

Nonneurologic causes of binocular diplopia for the neurologist

Nonneurologic causes of binocular diplopia for the neurologist

Surgical management of dysthyroid optic neuropathy: A systematic review

Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review

Contact Info

Product

Resources

About